Matrix Pharma preclinical data

MATX and independent collaborators presented preclinical data at the American Association for Cancer Research meeting in Washington on the ability of its anhydrous vehicle systems to deliver topoisomerase I and II inhibitors into tumors.

Topoisomerase I and II affect DNA binding, replication and repair. MATX's anhydrous vehicles have been developed to deliver lipophilic drugs and drugs with low water solubility or instability in an aqueous environment. ...